China Medical University | China
Dr. Yan Ding is a biomedical researcher with a doctorate from China Medical University, Shenyang. Her academic training includes a Bachelor’s degree from Shenyang Pharmaceutical University, a Master’s and PhD from China Medical University. Since 2013, she has progressed through roles in experimental research—assistant experimentalist, experimentalist, and since 2022, senior experimentalist—at the Institute of Metabolic Disease Research & Drug Development and the College of Basic Medical Science. Her research focuses on molecular and cellular mechanisms underlying lung injury, inflammation, epithelial sodium transport, miRNA regulation, pulmonary fibrosis and herbal / natural compounds’ effects. She has published numerous first-author papers addressing roles of miRNAs (e.g. miR-130a-3p, miR-199a-3p, miR-21), luteolin’s therapeutic potential, regulation of epithelial sodium channel (ENaC), anti-oxidant and anti-inflammatory pathways. she has an h-index of 6 with 143 citations overall. Throughout her career, she has also contributed to studies of lung fluid clearance, regulatory mechanisms during viral infections, and herbal monomers in edematous disorders. Awards include recognition for excellence in experimental work (institutional). In conclusion, Dr. Ding is an emerging researcher building a solid track record in pulmonary molecular biology, with demonstrated expertise in miRNAs, ion channel regulation, and translational potential in lung disease therapy.
Featured Publications
“Factors influencing the provision of public health services by village doctors in Hubei and Jiangxi provinces,
China”
“Practical actions for fostering cross-disciplinary global health research: lessons from a narrative literature review”
“Healthcare seeking behaviour among Chinese elderly”
“A cost-effectiveness analysis of three components of a syndromic surveillance system for the early warning of epidemics in rural China”
“Qualitative study exploring lessons from Liberia and the UK for building a people-centred resilient health system response to COVID-19”